Lingzhe He1, Buyi Zhang1, Jianmin Zhang1, Zhige Guo1, Feina Shi2, Qiang Zeng1. 1. Department of Neurosurgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. 2. Department of Neurology, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Abstract
BACKGROUND: It still remains unclear whether patients with atypical meningioma (AM) could benefit from postoperative adjuvant radiotherapy (PORT) after gross-total resection (GTR). OBJECTIVE: Exploring the effectiveness of PORT on AM patients after GTR. METHODS: Literatures on PubMed, Embase, Web of science, and Scopus databases published between January 2000 and January 2019 were searched. After the selection based on the certain exclusion criteria, the Newcastle-Ottawa evaluation scale was used to evaluate the quality of the included literatures. Finally, a meta-analysis was conducted to analyze the effectiveness of PORT on local control (LC), progression-free survival (PFS) and overall survival (OS) in atypical meningioma patients after GTR. RESULTS: A total of 17 articles with 2,008 AM patients were included in the meta-analysis. The 5-year LC, 5-year PFS, and 5-year OS rates were 82.2, 84.1, and 79.0%, respectively, for AM patients receiving PORT after GTR, and they were 71.0, 71.9, and 81.5%, respectively, for those not receiving PORT after GTR. PORT could significantly improve 5-year LC rate (OR [95% Cl] = 2.59 [1.40-4.81], P = 0.002) and 5-year PFS rate (OR [95% Cl] = 1.99 [1.35-2.95], P = 0.001), but did not significantly improve 5-year OS rate (OR [95% Cl] = 1.07 [0.60-1.91], P = 0.828). CONCLUSION: PORT could improve the 5-year LC rate and 5-year PFS rate in AM patients after GTR. AM patients might benefit from PORT after GTR.
BACKGROUND: It still remains unclear whether patients with atypical meningioma (AM) could benefit from postoperative adjuvant radiotherapy (PORT) after gross-total resection (GTR). OBJECTIVE: Exploring the effectiveness of PORT on AM patients after GTR. METHODS: Literatures on PubMed, Embase, Web of science, and Scopus databases published between January 2000 and January 2019 were searched. After the selection based on the certain exclusion criteria, the Newcastle-Ottawa evaluation scale was used to evaluate the quality of the included literatures. Finally, a meta-analysis was conducted to analyze the effectiveness of PORT on local control (LC), progression-free survival (PFS) and overall survival (OS) in atypical meningioma patients after GTR. RESULTS: A total of 17 articles with 2,008 AM patients were included in the meta-analysis. The 5-year LC, 5-year PFS, and 5-year OS rates were 82.2, 84.1, and 79.0%, respectively, for AM patients receiving PORT after GTR, and they were 71.0, 71.9, and 81.5%, respectively, for those not receiving PORT after GTR. PORT could significantly improve 5-year LC rate (OR [95% Cl] = 2.59 [1.40-4.81], P = 0.002) and 5-year PFS rate (OR [95% Cl] = 1.99 [1.35-2.95], P = 0.001), but did not significantly improve 5-year OS rate (OR [95% Cl] = 1.07 [0.60-1.91], P = 0.828). CONCLUSION: PORT could improve the 5-year LC rate and 5-year PFS rate in AM patients after GTR. AM patients might benefit from PORT after GTR.
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: Shaakir Hasan; Michael Young; Trevine Albert; Ashish H Shah; Christian Okoye; Amade Bregy; Simon S Lo; Fazilat Ishkanian; Ricardo J Komotar Journal: World Neurosurg Date: 2014-12-19 Impact factor: 2.104
Authors: Shakir I Shakir; Luis Souhami; Kevin Petrecca; Jose João Mansure; Khushdeep Singh; Valerie Panet-Raymond; George Shenouda; Amal A Al-Odaini; Bassam Abdulkarim; Marie-Christine Guiot Journal: J Neurosurg Date: 2018-11-01 Impact factor: 5.115
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A Fenstermaker; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh Journal: J Natl Compr Canc Netw Date: 2017-11 Impact factor: 11.908
Authors: Douglas A Hardesty; Andrew B Wolf; David G Brachman; Heyoung L McBride; Emad Youssef; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai Journal: J Neurosurg Date: 2013-02-08 Impact factor: 5.115
Authors: Chenyang Wang; Tania B Kaprealian; John H Suh; Charlotte D Kubicky; Jeremy N Ciporen; Yiyi Chen; Jerry J Jaboin Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300
Authors: Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti Journal: Neurosurg Rev Date: 2022-06-04 Impact factor: 2.800